HomeInsightsPE

Morepen Laboratories Ltd PE Ratio

Morepen Laboratories Ltd PE Ratio

stocks purchased

₹ 5.0 Cr

Volume Transacted

(Nov 25, 2024)

stocks purchased

675.4 K

Stocks Traded

(Nov 25, 2024)

Last Updated on: Nov 25, 2024

Image

Morepen Laboratories Ltd

NSE: MOREPENLAB

PE

30.9

Last updated on: Nov 25, 2024

Key Highlights

  • The P/E Ratio of Morepen Laboratories Ltd is 30.9 as of 25 Nov 15:30 PM .
  • The P/E Ratio of Morepen Laboratories Ltd changed from 27 on March 2019 to 22.4 on March 2024 . This represents a CAGR of -3.06% over 6 years.
  • The Latest Trading Price of Morepen Laboratories Ltd is ₹ 74.02 as of 25 Nov 15:45 .
  • The PE Ratio of Pharmaceuticals Industry has changed from 28.2 to 27.1 in 5 years. This represents a CAGR of -0.79%.
  • The PE Ratio of Automobile industry is 20.3. The PE Ratio of Finance industry is 17.8. The PE Ratio of IT - Software industry is 30.3. The PE Ratio of Pharmaceuticals industry is 40.0. The PE Ratio of Retail industry is 157.7. The PE Ratio of Textiles industry is 37.6 in 2024.

Historical P/E Ratio of Morepen Laboratories Ltd

No data available

Company Fundamentals for Morepen Laboratories Ltd

No data available

Image

Morepen Laboratories Ltd

NSE: MOREPENLAB

Share Price

₹ 74.02

-0.03 (-0.04%)

stock direction

Last updated on: Nov 25, 2024

Market Price of Morepen Laboratories Ltd

1M

1Y

3Y

5Y

Monitoring Morepen Laboratories Ltd share price can help you stay informed about potential market shifts and opportunities. *All values are in Rupees.

Last Ten Days Market Price

Date
leftPrice (₹)right
22 Nov 202474.05
21 Nov 202473.21
19 Nov 202475.87
18 Nov 202474.22
14 Nov 202475.62
13 Nov 202475.52
12 Nov 202479.94
11 Nov 202480.26
08 Nov 202483.31
07 Nov 202484.56

SWOT Analysis Of Morepen Laboratories Ltd

Strength

2

S

Weakness

2

W

Opportunity

0

O

Threats

0

T

BlinkX Score for Morepen Laboratories Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

Asset Value vs Market Value of Morepen Laboratories Ltd

Market Value

0

Asset Value

0

* All values are in Rupees

Competitive Comparison of P/E Ratio

Company NamePEMarket Cap (INR Cr.)
Morepen Laboratories Ltd304,057
Sun Pharmaceuticals Industries Ltd384,31,352
Divis Laboratories Ltd861,59,265
Cipla Ltd261,20,033
Torrent Pharmaceuticals Ltd611,07,301
Mankind Pharma Ltd481,02,231

Key Valuation Metric of Morepen Laboratories Ltd

No data available

No data available

PE Ratio of Pharmaceuticals Industry over time

PE Ratio of Top Sectors

Historical Market Cap of Morepen Laboratories Ltd

No data available

* All values are in crore

Historical Revenue of Morepen Laboratories Ltd

No data available

* All values are in crore

Historical EBITDA of Morepen Laboratories Ltd

No data available

* All values are in crore

Historical Net Profit of Morepen Laboratories Ltd

No data available

* All values are in crore

Historical Dividend Payout of Morepen Laboratories Ltd

No data available

* All values are in %

About Morepen Laboratories Ltd

  • Morepen Laboratories Limited is an India-based pharmaceutical company.
  • Its products include Loratadine, Montelukast Sodium, Atorvastatin Calcium and Sultamicillin.
  • The company markets formulation products in various therapeutic categories, such as antibiotics, gastrointestinal, respiratory, analgesic, antiallergic and neuropsychiatry with brands, such as Saltum, Saltumax, Cefpopen, Cefpen-S, Dom-DT, Acifix, Rabipen- DSR and Montelast.
  • It has new products added to the therapeutic categories, including Kilbac, Ducal D, Aclomore and Montelast-L. The company has three state-of-the-art manufacturing plants in the northern state of Himachal Pradesh (HP) in India.
  • The main plant at Parwanoo is inspected and approved by United States Food and Drug Administration (USFDA) for production of Loratadine, which is the best selling anti-allergy drug globally.

Morepen Laboratories Ltd News Hub

News

Morepen Labs soars after stellar Q1 performance

Net revenue increased by 14% year-over-year (YoY) to Rs 458.64 crore during the period und...

Read more

2024-08-12 00:00:00

News

Morepen Laboratories consolidated net profit rises 147.23% in the June 2024 quarter

Net profit of Morepen Laboratories rose 147.23% to Rs 36.17 crore in the quarter ended Jun...

Read more

2024-08-12 00:00:00

News

Morepen Laboratories to announce Quarterly Result

Morepen Laboratories will hold a meeting of the Board of Directors of the Company on 12 Au...

Read more

2024-08-10 00:00:00

News

Morepen Laboratories successfully concludes QIP issue of Rs 200 cr

Morepen Laboratories announced the successful subscription of a Qualified Institutional Pl...

Read more

2024-08-06 00:00:00

News

Morepen Laboratories appoints director

Morepen Laboratories has appointed Sharad Jain (DIN: 06423452) as an Independent Director,...

Read more

2024-08-27 00:00:00

Product Composition

Document

Annual Reports

N/A

dropdown
download

Credit Ratings

N/A

dropdown
download

Concalls

Data not available

FAQs for PE of Morepen Laboratories Ltd

What is the current PE Ratio of Morepen Laboratories Ltd?

The Current PE Ratio of Morepen Laboratories Ltd is 30.85 as on 25 Nov 2024.

What is the average PE Ratio of the Pharmaceuticals industry?

The average industry PE Ratio of Pharmaceuticals is 40.0 as on 25 Nov 2024.

What was the PE Ratio of Morepen Laboratories Ltd last year?

The PE Ratio of Morepen Laboratories Ltd was 33.79 last year, now the PE ratio is 30.85, showing a year-on-year growth of -8.7%.

What does the PE Ratio of Morepen Laboratories Ltd indicate about its stock?

The PE Ratio of Morepen Laboratories Ltd is 30.85. This ratio indicates that investors are willing to pay 30.85 times the earnings per share for each share of Morepen Laboratories Ltd.

What is the PE Ratio Growth of Morepen Laboratories Ltd in comparison to its Earnings per Share (EPS) growth rate?

The PE Ratio of Morepen Laboratories Ltd grew by -8.7% whereas, the EPS ratio grew by -8.5.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
50yearstrust

Unlimited trading at just

Rs. 399

Rs. 199*